Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis

patientMpower

Status

Completed

Conditions

Idiopathic Pulmonary Fibrosis

Treatments

Other: patientMpower platform

Other: usual care

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03104322

IPF patientMpower 02

Details and patient eligibility

About

Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of patientMpower platform from patient & healthcare professional perspective, impact of active engagement and self-monitoring using patientMpower platform on Patient Reported Outcome Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and correlation between patient-reported PROMs & FVC and clinical outcomes.

Enrollment

7 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

confirmed diagnosis of idiopathic pulmonary fibrosis (IPF).
daily unrestricted access to smartphone or tablet device at home.
demonstrated understanding of protocol and correct use of Spirobank Smart spirometer and patientMpower platform.
able and willing to perform spirometry every day at home.
willing to give written informed consent

Exclusion criteria

significant confusion or any concomitant medical condition which would limit the ability of the patient to record symptoms or use a home spirometer on a regular basis.
new prescription of antifibrotic therapy for IPF (e.g. pirfenidone, nintedanib) within 4 weeks before baseline visit.
recent exacerbation of IPF or other clinically significant change in the patient's medical condition in 4 weeks before baseline visit